Download PDF
Thromb Haemost 2001; 85(01): 5-11
DOI: 10.1055/s-0037-1612655
Rapid Communications
Schattauer GmbH

Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin

Laurent O. Mosnier
1   Thrombosis and Haemostasis Laboratory, Dept. of Haematology, University Medical Center, Utrecht, and Institute of Biomembranes, Utrecht University, Utrecht, The Netherlands
,
Joost C. M. Meijers   1
1   Thrombosis and Haemostasis Laboratory, Dept. of Haematology, University Medical Center, Utrecht, and Institute of Biomembranes, Utrecht University, Utrecht, The Netherlands
,
Bonno N. Bouma
1   Thrombosis and Haemostasis Laboratory, Dept. of Haematology, University Medical Center, Utrecht, and Institute of Biomembranes, Utrecht University, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 22 February 2000

Accepted after revision 08 May 2000

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme, that after activation down regulates fibrinolysis. TAFI is activated by thrombin in the presence of the cofactor thrombomodulin (TM). By stimulation of TAFI activation TM down regulates fibrinolysis, however TM is also a cofactor in the activation of protein C. Activated protein C (APC) can up regulate fibrinolysis by limiting the activation of TAFI via the attenuation of thrombin production. We studied these counteracting fibrinolytic properties of TM in plasma by measuring the activation of TAFI during tissue factor induced coagulation. TAFI activation was stimulated at low concentrations of TM but decreased at higher concentrations of TM. Similarly, the clot lysis times increased at low concentrations of TM but decreased at higher concentrations of TM. The reduction of TAFI activation at high TM concentrations was found to be dependent on a functional protein C pathway. The concentration of TM is therefore an important factor in the regulation of TAFI activation and in the regulation of fibrinolysis. High concentrations of TM result in up regulation of fibrinolysis, whereas low concentrations of TM have a down regulatory effect on fibrinolysis. These results suggest that fibrinolysis might be differentially regulated by TM in different parts of the body depending on the local TM concentration in the vasculature.

Abbreviations: TAFI, thrombin activatable fibrinolysis inhibitor; TAFIa, activated TAFI; CPI, carboxypeptidase inhibitor from potato tubers; tPA, tissue-type plasminogen activator; TM, thrombo-modulin; TM4-6, Thrombomodulin fragment containing EGF domains 4 to 6; HMEC, human microvascular endothelial cell.

Keywords

Coagulation - fibrinolysis - thrombomodulin - TAFI - protein C

1 Present address: Dr. J. C. M. Meijers, Dept. Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands


 

  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation and atherosclerosis. FASEB J 1995; 9: 934-8.
    CrossrefPubMedGoogle Scholar
  • 3 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
    PubMedGoogle Scholar
  • 4 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
    CrossrefPubMedGoogle Scholar
  • 5 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
    PubMedGoogle Scholar
  • 6 Vanhoof G, Schatteman K, Goossens F, Scharpe S, Hendriks D. Procarboxypeptidase U is expressed in human liver. Fibrinolysis Proteolysis 1997; 11: 41 (Abstract).
    PubMedGoogle Scholar
  • 7 Mosnier LO, Von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
    PubMedGoogle Scholar
  • 9 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
    CrossrefPubMedGoogle Scholar
  • 10 Wang W, Boffa PB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
    CrossrefPubMedGoogle Scholar
  • 11 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
    CrossrefPubMedGoogle Scholar
  • 12 Von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
    PubMedGoogle Scholar
  • 13 Von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
    CrossrefPubMedGoogle Scholar
  • 14 Bouma BN, Von dem Borne PAK, Meijers JCM. Factor XI and protection of the fibrin clot against lysis. A role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
    CrossrefPubMedGoogle Scholar
  • 16 Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
    CrossrefPubMedGoogle Scholar
  • 17 Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost 1997; 78: 427-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-52.
    CrossrefPubMedGoogle Scholar
  • 19 de Fouw NJ, Haverkate F, Bertina RM. Protein C and fibrinolysis: a link between coagulation and fibrinolysis. Adv Exp Med Biol 1990; 281: 235-43.
    PubMedGoogle Scholar
  • 20 Bajzar L, Fredenburgh JC, Nesheim ME. The activated protein C-mediated enhancement of tissue-type plasminogen activator induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 16948-54.
    PubMedGoogle Scholar
  • 21 Bajzar L, Nesheim M. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993; 268: 8608-16.
    PubMedGoogle Scholar
  • 22 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
    PubMedGoogle Scholar
  • 23 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-52.
    CrossrefPubMedGoogle Scholar
  • 24 Broze Jr GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
    PubMedGoogle Scholar
  • 25 Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998; 79: 371-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
    CrossrefPubMedGoogle Scholar
  • 27 Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2792-8.
    CrossrefPubMedGoogle Scholar
  • 28 Taylor Jr FB, Lockhart MS. Whole blood clot lysis: in vitro modulation by activated protein C. Thromb Res 1985; 37: 639-49.
    CrossrefPubMedGoogle Scholar
  • 29 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 1221-8.
    CrossrefPubMedGoogle Scholar
  • 30 Colluci M, Stassen JM, Collen D. Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. J Clin Invest 1984; 74: 200-4.
    CrossrefPubMedGoogle Scholar
  • 31 Burdick MD, Schaub RG. Human protein C induces anticoagulation and increased fibrinolytic activity in the cat. Thromb Res 1987; 45: 413-9.
    CrossrefPubMedGoogle Scholar
  • 32 Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden. J Biol Chem 1996; 271: 22949-52.
    CrossrefPubMedGoogle Scholar
  • 33 Nowak Gottl U, Vielhaber H, Grohmann J, Schneppenheim R, Koch HG. Arginine 506 to glutamine mutation in the factor V gene in infancy and childhood: evidence of fibrinolytic impairment. Eur J Pediatr 1997; 156: 195-8.
    CrossrefPubMedGoogle Scholar
  • 34 Meijers JCM. Regulation of the blood coagulation mechanism by plasma proteinase inhibitors. Ph D Thesis State University of Utrecht; 1988: 93-108.
    PubMedGoogle Scholar
  • 35 Hackeng TM, Hessing M, van ’t Veer C, Meijer-Huizinga F, Meijers JCM, de Groot PG, van Mourik JA, Bouma BN. Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. J Biol Chem 1993; 268: 3993-4000.
    PubMedGoogle Scholar
  • 36 Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-90.
    CrossrefPubMedGoogle Scholar
  • 37 Kokame K, Zheng XL, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273: 12135-9.
    CrossrefPubMedGoogle Scholar
  • 38 Wang W, Nagashima M, Morser J, Nesheim M. Comparison of the structures of thrombomodulin required for the activation of protein C and TAFI. Fibrinolysis Proteolysis 1998; 12: 11 (Abstract).
    PubMedGoogle Scholar
  • 39 Braat EAM, Los P, Rijken DC. The inactivation of single-chain urokinasetype plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. Blood Coagul Fibrinolysis 1998; 9: 419-27.
    CrossrefPubMedGoogle Scholar
  • 40 Le Bonniec BF, MacGillivray RT, Esmon CT. Thrombin Glu-39 restricts thr P’3 specificity to nonacidic residues. J Biol Chem 1991; 266: 13796-803.
    PubMedGoogle Scholar
  • 41 Parkinson JF, Grinnell BW, Moore RE, Hoskins J, Vlahos CJ, Bang NU. Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. J Biol Chem 1990; 265: 12602-10.
    PubMedGoogle Scholar
  • 42 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and disease. Blood 1990; 76: 2024-9.
    PubMedGoogle Scholar
  • 43 Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenviroment. J Cell Biol 1997; 138: 1117-24.
    CrossrefPubMedGoogle Scholar
  • 44 Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-52.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67: 362-5.
    PubMedGoogle Scholar
  • 46 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
    PubMedGoogle Scholar
  • 47 Busch C, Cancilla PA, DeBault LE, Goldsmith JC, Owen WG. Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 1982; 47: 498-504.
    PubMedGoogle Scholar
  • 48 Griffin JH. The thrombin paradox. Nature 1995; 378: 337-8.
    CrossrefPubMedGoogle Scholar